본문으로 건너뛰기
← 뒤로

Clinical value of CTCs combined with serum tumor markers/inflammatory cytokines for the early diagnosis of non-small cell lung cancer.

1/5 보강
Immunobiology 2026 Vol.231(2) p. 153161
Retraction 확인
출처

PICO 자동 추출 (휴리스틱, conf 2/4)

유사 논문
P · Population 대상 환자/모집단
추출되지 않음
I · Intervention 중재 / 시술
surgical treatment at the Fourth Hospital of Hebei Medical University between November 2021 and December 2022
C · Comparison 대조 / 비교
추출되지 않음
O · Outcome 결과 / 결론
The combination of IL-17 A and CTCs achieved an AUC of 0.953, with a sensitivity of 86.05% and specificity of 90.00%. [CONCLUSION] The integration of CTCs with serum tumor markers and/or inflammatory cytokines provides high sensitivity and specificity for the diagnosis of early-stage NSCLC, highlighting its significant clinical potential.

Gu X, Wan L

📝 환자 설명용 한 줄

[OBJECTIVE] This study investigates the clinical utility of circulating tumor cells (CTCs) in combination with serum tumor markers/inflammatory cytokines for the diagnosis of early-stage non-small cel

🔬 핵심 임상 통계 (초록에서 자동 추출 — 원문 검증 권장)
  • p-value P < 0.05
  • Sensitivity 65.12%
  • Specificity 100.00%

이 논문을 인용하기

↓ .bib ↓ .ris
APA Gu X, Wan L (2026). Clinical value of CTCs combined with serum tumor markers/inflammatory cytokines for the early diagnosis of non-small cell lung cancer.. Immunobiology, 231(2), 153161. https://doi.org/10.1016/j.imbio.2026.153161
MLA Gu X, et al.. "Clinical value of CTCs combined with serum tumor markers/inflammatory cytokines for the early diagnosis of non-small cell lung cancer.." Immunobiology, vol. 231, no. 2, 2026, pp. 153161.
PMID 41650702 ↗

Abstract

[OBJECTIVE] This study investigates the clinical utility of circulating tumor cells (CTCs) in combination with serum tumor markers/inflammatory cytokines for the diagnosis of early-stage non-small cell lung cancer (NSCLC).

[METHODS] A retrospective analysis was conducted on the clinical data of 43 NSCLC patients (stage I-IIA) who underwent surgical treatment at the Fourth Hospital of Hebei Medical University between November 2021 and December 2022. A control group of 50 healthy individuals was also included. Comparative analyses of CTCs, serum tumor markers, and inflammatory cytokine levels were performed between the two groups. The clinical diagnostic value was assessed using receiver operating characteristic (ROC) curve analysis.

[RESULTS] The median concentrations of CTCs, carcinoembryonic antigen (CEA), Cytokeratin 19 fragment (CYFRA21-1), neuron-specific enolase (NSE), interleukin-4 (IL-4), interleukin-6 (IL-6), interleukin-10 (IL-10), tumor necrosis factor-alpha (TNF-α), and interleukin-17 A (IL-17 A) were significantly elevated in the NSCLC cohort compared to the healthy control cohort, while interleukin-2 (IL-2) levels were reduced (P < 0.05). ROC curve analysis revealed that CTCs exhibited a sensitivity of 65.12%, specificity of 100.00%, and an area under the curve (AUC) of 0.826 for the diagnosis of early-stage NSCLC. The combined diagnostic sensitivity of CTCs, CEA, CYFRA21-1, and NSE reached 86.05%, with 100.00% specificity and an AUC of 0.945. Among the seven inflammatory cytokines evaluated, IL-17 A exhibited the highest diagnostic efficacy for early-stage NSCLC, with an AUC of 0.871, sensitivity of 93.02%, and specificity of 75.00%. The combination of IL-17 A and CTCs achieved an AUC of 0.953, with a sensitivity of 86.05% and specificity of 90.00%.

[CONCLUSION] The integration of CTCs with serum tumor markers and/or inflammatory cytokines provides high sensitivity and specificity for the diagnosis of early-stage NSCLC, highlighting its significant clinical potential.

🏷️ 키워드 / MeSH 📖 같은 키워드 OA만

… 외 2개

같은 제1저자의 인용 많은 논문 (5)

🏷️ 같은 키워드 · 무료전문 — 이 논문 MeSH/keyword 기반